Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 1/20 | 0.36 |
| ▸ | CYP19A1 known ✓ | P11511 | 1/20 | 0.35 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.34 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.33 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.33 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.32 |
| ▸ | SLC6A2 known ✓ | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1742546 | 1.00 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| Hydrochloric Acid SCHEMBL28281808 | 0.97 | MEN1 (0.37) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| SCHEMBL1706403 | 0.97 | MEN1 (0.39) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| SCHEMBL5387 | 0.97 | — | — | |
| SCHEMBL77101 | 0.97 | — | — | |
| SCHEMBL12403231 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| SCHEMBL4822887 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| SCHEMBL13509549 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| Iodide SCHEMBL30375035 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 | |
| Piperazine SCHEMBL28179364 | 0.94 | MEN1 (0.38) | MEN1KMT2ACHRNA7CYP2D6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102659718-B | Prepare the method for cyclopropyl-amide derivatives | JANSSEN PHARMACEUTICA N. V. (BE) | 2015-11-25 | — | — | CN | disclosed |
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | MANI NEELAKANDHA S (US) | 2012-11-08 | — | — | US | disclosed |
| EP-1951699-B1 | PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-10 | — | — | EP | disclosed |
| CN-102659718-A | Processes for the preparation of cyclopropyl-amide derivatives | JANSSEN PHARMACEUTICA NV | 2012-09-12 | — | — | CN | disclosed |
| CN-101300242-B | Process for preparing cyclopropyl-amide derivatives | JANSSEN PHARMACEUTICA NV | 2012-07-11 | — | — | CN | disclosed |
| US-20120029191-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | MANI NEELAKANDHA S (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2404911-A1 | Novel processes for the preparation of piperazinyl and diazapanyl benzamide derivatives | Janssen Pharmaceutica NV (BE) | 2012-01-11 | — | — | EP | disclosed |
| US-8063206-B2 | Processes for the preparation of cyclopropyl-amide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2011-11-22 | — | — | US | disclosed |
| US-7947718-B2 | Isoxazole compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-24 | — | — | US | disclosed |
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| US-5190974-A | Analgesics | ROUSSEL UCLAF (FR) | 1993-03-02 | — | — | US | disclosed |
| EP-0465369-A1 | N-substituted derivatives of alpha-mercapto alkylamines, process for their preparation and intermediates obtained, their use as medicaments and compositions containing them | ROUSSEL-UCLAF (FR) | 1992-01-08 | — | — | EP | disclosed |
| EP-0459819-A2 | Pharmacologically active CNS compound | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-12-04 | — | — | EP | disclosed |
| US-5039676-A | Fungicide, antiallergens | SCHERING CORPORATION (US) | 1991-08-13 | — | — | US | disclosed |
| EP-0386143-A1 | TRI- AND TETRA-SUBSTITUTED-OXETANES AND TETRAHYDROFURANS AND INTERMEDIATES THEREOF | SCHERING CORPORATION (US) | 1990-09-12 | — | — | EP | disclosed |
| WO-1989004829-A1 | TRI- AND TETRA-SUBSTITUTED-OXETANES AND TETRAHYDROFURANS AND INTERMEDIATES THEREOF | SCHERING CORPORATION (US) | 1989-06-01 | — | — | WO | disclosed |
| EP-0318214-A1 | Tri- and tetra-substituted-oxetanes and -tetrahydrofurans and intermediates thereof | SCHERING CORPORATION (US) | 1989-05-31 | — | — | EP | disclosed |
| EP-0090424-B1 | NEW QUINOLONE COMPOUNDS AND PREPARATION THEREOF | STERLING DRUG INC. (US) | 1986-05-28 | — | — | EP | disclosed |
| US-4499091-A | 1-Amino (or substituted amino)-1,4-dihydro-4-oxo-6-fluoro-7-heterylquinoline-3-carboxylic acids and their use as antibacterial agents | STERLING DRUG INC. (US) | 1985-02-12 | — | — | US | disclosed |
| EP-0090424-A1 | New quinolone compounds and preparation thereof | STERLING DRUG INC. (US) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | CHRNA7 289/4885CYP19A1 1886/4885CHRM2 201/4885 |
| US-20120029191-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | CHRNA7 289/4885CYP19A1 1886/4885CHRM2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.